Aptamers Market
Number of pages: 100 | Report Format: PDF | Published date: April 21, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 2.59 Billion |
|
Revenue Forecast in 2031 |
US$ 11.42 Billion |
|
CAGR |
17.90% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Type, Technology, Application, End User, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global aptamers market was valued at US$ 2.59 billion in 2022 and is expected to register a revenue CAGR of 17.90% to reach US$ 11.42 billion by 2031.
Aptamers Market Fundamentals
Aptamers are short, single-stranded nucleic acids or peptides that bind specifically to target molecules, such as proteins, small molecules, and even whole cells. They are selected in vitro from a large library of random sequences using the Systematic Evolution of Ligands by Exponential Enrichment (SELEX). Aptamers can be designed to bind to a wide range of targets with high specificity and affinity. Depending on the desired application, they can be tailored to have various binding properties, such as reversible or irreversible. They have several advantages over traditional antibody-based approaches, including low immunogenicity, high stability, easy synthesis, and modification. Aptamers have found various applications in biosensing, diagnostics, therapeutics, and drug delivery. They are being explored as potential alternatives to traditional antibodies for clinical use due to their advantageous properties, and regulatory agencies have already approved several aptamer-based drugs.
[21]
Aptamers Market Dynamics
The use of aptamers in various applications such as drug discovery, diagnostics, and therapeutics has increased in recent years, leading to a rise in research and development activities. Technological advancements in developing and synthesizing aptamers have enabled their widespread use in various applications. The prevalence of chronic diseases such as cancer, diabetes, and cardiovascular diseases has been increasing, leading to a higher demand for aptamers for their potential use as diagnostic and therapeutic agents. The biotechnology and pharmaceutical industries are investing heavily in the development and commercialization of aptamers, driving the growth of the global aptamers market revenue. Aptamers have the potential to be used in personalized medicine due to their high specificity and selectivity, which is driving the demand for their use in this field.
Aptamer development and manufacturing require significant technological, expertise, and time investments. This can make it challenging for smaller companies to enter the market and compete with larger players. Despite their potential benefits, aptamers are still relatively unknown to many researchers and clinicians. This limited awareness can make generating demand for aptamer-based products and services challenging. Aptamers are considered novel therapeutic agents, and as such, they are subject to rigorous regulatory oversight by health authorities such as the FDA. Meeting these requirements can be time-consuming and expensive. Aptamers face competition from established technologies such as monoclonal antibodies, which have a proven efficacy and safety track record. This can make it challenging for aptamers to gain traction in the market. The development of high-quality aptamers requires extensive expertise and resources. As a result, a limited supply of high-quality aptamers is available for research and therapeutic use.
Aptamers Market Ecosystem
The global aptamers market has been analyzed from five perspectives: type, technology, application, end-user, and region.
Aptamers Market by Type
[32]
Based on type, the global aptamers market is segmented into nucleic acid and peptide.
Nucleic acid aptamers have high binding affinity and specificity towards their target molecules, making them ideal for various applications. Nucleic acid aptamers are more stable than protein aptamers, and they do not require cold storage or special handling, which reduces their cost and makes them easier to use. Nucleic acid aptamers can be easily synthesized in large quantities using chemical synthesis methods, making them more versatile and cost-effective than other aptamers. Nucleic acid aptamers are non-immunogenic, which means they do not trigger an immune response in the body. This makes them ideal for diagnostics and therapeutics, where the immune response can be a significant problem. Nucleic acid aptamers are small, allowing them to penetrate tissues and cells more easily than larger molecules, such as antibodies.
Aptamers Market by Technology
Based on technology, the global aptamers market is segmented into SELEX, MARAS Technique, and X-aptamers.
The SELEX segment accounts for the largest revenue share in the global market. Systematic Evolution of Ligands by Exponential Enrichment (SELEX) is a widely used method for selecting aptamers. SELEX is a well-established and widely used method for the selection of aptamers. It has been used successfully to select aptamers for various targets, including proteins, small molecules, and cells. SELEX has a high success rate in identifying aptamers with high binding affinity and specificity towards their target molecules. SELEX can be used to select aptamers for various applications, including diagnostics, therapeutics, and biosensors. SELEX can be easily scaled up to generate large quantities of aptamers for commercial applications. Several companies offer commercial SELEX kits, making selecting aptamers easier for researchers and companies. SELEX is a well-established method, and regulatory agencies have approved aptamers selected using SELEX for use in diagnostics and therapeutics.
Aptamers Market by Application
Based on application, the global aptamers market is segmented into diagnostics, therapeutics, research and development, and others.
The diagnostics segment dominates the global aptamers market with the largest revenue share. Aptamers have high specificity towards their target molecules, making them ideal for diagnostic assays. They can detect small changes in the concentration of target molecules, which is important for the early detection of diseases. Aptamers have high sensitivity, which allows them to detect low concentrations of target molecules. This is particularly important for the detection of diseases in the early stages. Aptamers can be easily modified to detect target molecules, making them versatile for various diagnostic assays. Aptamers are cost-effective compared to traditional diagnostic methods, such as antibodies. They can be easily synthesized in large quantities, which reduces the cost of manufacturing diagnostic assays.
Aptamers Market by End User
Based on the end user, the global aptamers market is segmented into pharmaceutical & biotechnology companies, academic & government research institutes, and CROs.
The pharmaceutical and biotechnology companies segment dominates the global aptamers market with the largest revenue share. Aptamers have shown great potential for therapeutic applications such as cancer treatment, drug delivery, and molecular imaging. Pharmaceutical and biotechnology companies are actively exploring using aptamers in developing new drugs and therapies. Pharmaceutical and biotechnology companies invest heavily in research and development to discover new drugs and therapies. Aptamers offer a unique opportunity for drug development due to their high specificity and low toxicity, making them an attractive alternative to traditional small-molecule drugs. The development of aptamers requires a significant investment of time and resources, including research and development costs. Pharmaceutical and biotechnology companies can protect their investment by obtaining patents on their aptamer-based products, providing a competitive advantage in the market. Pharmaceutical and biotechnology companies have the expertise and resources to navigate the regulatory process for drug approval, which can be a significant barrier to entry for smaller companies. The regulatory approval process is necessary to ensure the safety and efficacy of new drugs. Companies with experience in this area are better positioned to bring aptamer-based therapies to market.
Aptamers Market by Region
Based on the region, the global aptamers market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America has a strong research and development infrastructure, including academic institutions, government research organizations, and private companies. This infrastructure supports the development of new aptamer-based products and applications. North America was an early adopter of aptamer technology, which has given companies and researchers in the region a competitive advantage in developing and commercializing aptamer-based products. North America's well-established regulatory environment provides a clear pathway for developing and approving aptamer-based products. Several funding agencies and organizations in North America support research and development in the field of aptamers, which has helped accelerate the development of new products and applications. Many key players in the aptamer market, including aptamer developers, research organizations, and diagnostic companies, are located in North America, which has helped establish the region as a hub for aptamer research and development.
Europe accounts for the second largest revenue share in the global market, attributed to the rapid adoption of advanced technologies, well-developed healthcare facilities, and growing incidences of chronic diseases. Similarly, Asia Pacific is also expected to rise rapidly in terms of revenue share from 2022 to 2031. The market revenue growth in this region can be attributed to various factors, such as rapidly growing healthcare infrastructure, increasing cases of chronic diseases, and the growing adoption of technological advancements.
Aptamers Market Competitive Landscape
A promising product pipeline, new product approvals, and strategic acquisitions and partnerships provide a competitive edge to the market. The prominent players operating in the global aptamers market are:
Aptamers Market Competitive Landscape
Aptamers are short, single-stranded nucleic acids or peptides that bind specifically to target molecules, such as proteins, small molecules, and even whole cells. They are selected in vitro from a large library of random sequences using Systematic Evolution of Ligands by Exponential Enrichment (SELEX).
NeoVentures Biotechnology Inc., Kaneka Corporation, Aptus Biotech, and Novaptech are some of the major market players operating in the global aptamers market.
Aptamer development and manufacturing require significant technological investments, expertise, and time. This can make it challenging for smaller companies to enter the market and compete with larger players.
SELEX segment dominates the global aptamers market with the largest revenue share.
The use of aptamers in various applications such as drug discovery, diagnostics, and therapeutics has increased in recent years, leading to a rise in research and development activities, enhancing the market revenue growth.
*Insights on financial performance are subject to the availability of information in the public domain